Table 4.
PRRT therapeutic efficacy.
| Modality | Best response | Frequency | PFS (mean ± SD (months)) | PFS (median (months)) | |
|---|---|---|---|---|---|
| PRRT alone | CR | 0/35 | 0% | ||
| PR | 12/35 | 34% | 28.0 ± 28.2 | 17 | |
| SD | 19/35 | 54% | |||
| PD | 3/35 | 9% | |||
| MR | 1/35 | 3% | |||
|
| |||||
| PRRT + SSA | CR | 0/30 | 0% | ||
| PR | 16/30 | 53% | 31.7 ± 18.1 | 27 | |
| SD | 14/30 | 47% | |||
| PD | 0/30 | 0% | |||
| MR | 0/30 | 0% | |||